期刊文献+

低频超声波促进重酒石酸卡巴拉汀经皮渗透的研究 被引量:3

Study on Enhancements of Low Frequency Ultrasound to Percutaneous Permeability of Rivastigmine Hydrogen Tartrate
原文传递
导出
摘要 目的研究低频超声波对重酒石酸卡巴拉汀(rivastigmine hydrogen tartrate,RHT)经皮渗透的促进作用。方法通过对小鼠、大鼠、小型猪和乳猪皮肤性能的考察,选择乳猪腹部皮肤进行经皮渗透实验。采用20 k Hz的超声波,于单室扩散池中测定2%的RHT水溶液的经皮渗透速率,考察超声波强度和暴露时间的影响。结果当超声波暴露时间为3 min时,超声波强度从2 W·cm?2增加到11 W·cm?2,超声波对RHT的促渗倍数从9.15倍增加到84.79倍。超声波强度为2 W·cm?2时,超声时间从3 min增加到30 min,促渗倍数从9.15倍增加到42.85倍。结论低频超声波对RHT有很强的经皮渗透促进作用,增加超声的功率或者延长超声的时间,均能够明显增强超声对RHT的促渗作用。 OBJECTIVE To investigate the promoting effect of low frequency ultrasound on percutaneous penetration of rivastigmine hydrogen tartrate. METHODS Through investigating the skin performance of mice, rats, miniature pig and suckling pig, the suckling pig abdominal skin was used in percutaneous experiments. The percutaneous permeability of 2% rivastigmine tartrate solution was determined in one- chamber diffusion cell using 20 k Hz ultrasoun. The effects of ultrasonic intensity and exposure time on enhancement were evaluated. RESULTS When the ultrasonic exposure time of 3 min, ultrasonic intensity was increased from 2 to 11 W·cm·2, the enhance rate increased to 84.79 times from 9.15 times. Ultrasonic intensity of 2 W·cm·2, ultrasonic time increased from 3 to 30 min, the enhance rate increased from 9.15 to 42.85 times. CONCLUSION Low frequency ultrasound can be effectively used to enhance transdermal delivery of rivastigmine hydrogen tartrate. The increase of ultrasonic intensity or extension of ultrasonic time, can significantly enhance the penetration effect.
出处 《中国现代应用药学》 CAS CSCD 2015年第4期455-459,共5页 Chinese Journal of Modern Applied Pharmacy
关键词 重酒石酸卡巴拉汀 超声波 经皮给药 皮肤 rivastigmine hydrogen tartrate ultrasound transdermal drug delivery skin
  • 相关文献

参考文献15

  • 1吴佳莹,羊红玉,赵青威,张相宜,张幸国.抗阿尔茨海默病的新靶点及药物研发进展[J].中国医院药学杂志,2013,33(19):1615-1618. 被引量:6
  • 2毛政,周东升,周萍,郑宏,刘小北.浙江省3家医院阿尔茨海默病患者医院感染现状及病原菌特点和耐药性分析[J].中国现代应用药学,2013,30(12):1359-1363. 被引量:4
  • 3BUMS A, SPIEGEL R, QUARG P. Efficacy of rivasfigmine in subjects with moderately severe Alzheimers disease [J]. lnt J Geriatr Psychiatry, 2004, 19(4): 243-249.
  • 4TSE FL, LAPLANCHE R. Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration [J]. Pharm Res, 1998, 15(10): 1614-1620.
  • 5AGNES L F, YIE W C, SHUN J L. Transdermal delivery of treatment for alzheimer's disease development, clinical performance and Future prospects [J]. Drugs Aging, 2008, 25(9): 761-775.
  • 6KURZ A, FARLOW M, LEFEVRE G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review [J]. 2009, 3(5): 799-805.
  • 7PARK D, PARK H, SEO J, et al. Sonophoresis in transdermal drug dcliverys [J]. Ultrasonics, 2014, 54(1): 56-65.
  • 8梁哲浩,梁文权,孙华琴.超声波促进盐酸利多卡因经皮渗透的研究[J].中国现代应用药学,2014,31(4):437-441. 被引量:10
  • 9AZAGURY A, KHOURY L, ENDE G, et al. Ultrasound mediated transdermal drug delivery [J]. Adv Drug Deliv Rev, 2014, 72(1): 127-143.
  • 10TEZEL A, SENS A, TUCHSCHERER J, et al. Frequency dependence of sonophoresis [J]. Pharm Res, 2001, 18(12): 1694-1700.

二级参考文献41

  • 1黄亮,陈志良,李国锋,朱晓亮,刘婵.利多卡因酊剂和微乳制剂体外经皮渗透实验研究[J].南方医科大学学报,2007,27(4):541-542. 被引量:13
  • 2Lyseng Williamson KA, McKeage K. Once-daily memantine: a guide to its use in moderate to severe aizheimer' s disease in the EU[J] Drugs Aging,2013, 30: 51-58.
  • 3Hopkins CR. ACS chemical neuroscience molecule spotlight on semagacestat (LY450139)[J]. ACS Chem Neurosci,2010, 1: 533-534.
  • 4Vassar R, Kandalepas PC. The beta-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease[J]. Alzheimers Res Ther,2011,3 : 20.
  • 5Coric V, van Dyck CH, Salloway S, etal. Safety and tolerabil- ity of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate alzheimer disease[J]. Arch Neurol, 2012, 1-12.
  • 6Kandalepas PC, Vassar R. Identification and biology of beta- secretase[J]. J Neuroehem,2012,120(Suppl 1): 55-61.
  • 7Ryan JM, Grundman M. Anti-amyloid-beta immunotherapy in Alzheimer's disease: AC@001 clinical trials are ongoing[J]. J Alzheimers Dis,2009, 17: 243.
  • 8Vincent B, Govitrapong P. Activation of the alpha-secretase processing of AbetaPP as a therapeutic approach in Alzheimer's disease[J]. J Alzheimers Dis,2011, 24(Suppl 2):75-94.
  • 9Salloway S, Sperling R, Keren R, etal. A phase 2 randomized trial of ELNI)005, scyllo-inositol, in mild to moderate Alzhei- mer disease[J] Neurology,2011, 77: 1253-1262.
  • 10Delrieu J, Ousset PJ, Caillaud C, et al. Clinical trials in Alzhe- imer's disease: immunotherapy approaches[J]. J Neurochem, 2012,120(Suppl 1): 186 193.

共引文献16

同被引文献30

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部